IFNA2 and renal cell carcinoma: Similar symptoms were reported in a study among 70 patients, 57 of whom had RCC, receiving doses of pegylated interferon alpha-2B administered subcutaneously for 4 weeks [13], including fatigue (38%), pain (34%), weight loss (28%), and dyspnea (21%).